Vedolizumab in ulcerative colitis: clinical case

Tarasova L.V.

Surgut State University;
I.N. Ulyanov Chuvash State University;
Surgut District Clinical Hospital

SPIN RSCI: 4125-7935
Scopus AuthorID: 35777248600
ORCID: 0000-0003-1496-0689

Busalaeva E.I.

Institute for Advanced Medical Studies;
I.N. Ulyanov Chuvash State University

Tsyganova Yu.V.

I.N. Ulyanov Chuvash State University

Zhudtlina N.V.

Surgut District Clinical Hospital

Matysyakevich I.D.

Surgut District Clinical Hospital

Vedolizumab in ulcerative colitis: clinical case

Authors:

Tarasova L.V., Busalaeva E.I., Tsyganova Yu.V., Zhudtlina N.V., Matysyakevich I.D.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2020;9(3): 77‑82

DOI: 10.17116/dokgastro2020903177

Downloaded: 292

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Tarasova LV, Busalaeva EI, Tsyganova YuV, Zhudtlina NV, Matysyakevich ID. Vedolizumab in ulcerative colitis: clinical case. Russian Journal of Evidence-Based Gastroenterology. 2020;9(3):77‑82. (In Russ.)
https://doi.org/10.17116/dokgastro2020903177

Подписка 2025 (Russian Journal of Evidence-Based Gastroenterology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Advancing differential diagnosis in inflammatory bowel diseases: a combined model approach integrating erythrocyte parameters, inflammation markers, erythrocyte membranes fatty acids, and blood serum profiles. Russian Journal of Evidence-Based Gastroenterology. 2023;(4):75-88

Bacterial microbiota in exacerbation of chronic purulent otitis media in children. Russian Bulletin of Otorhinolaryngology. 2023;(5):7-11

Experience of clinical use of fluvoxamine for the treatment of comorbid depression in childhood and adolescence. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(11-2):14-21

Sexual dysfunction on the background of antidepressant therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(11-2):115-121

Pseudotumorous form of primary central nervous system vasculitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(12):141-147

The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):82-88

Reflexology in patient rehabilitation with postoperative pain. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2023;(6):103-106

Russian multiple-center study of efficacy and safety of cyclobenzaprine for nonspecific neck and low back pain. Russian Journal of Pain. 2024;(1):27-33

Successful combinations of drug and non-drug therapy for low back pain. Russian Journal of Pain. 2024;(1):57-67

Traumatic damage to the diaphragm in children. Pirogov Russian Journal of Surgery. 2024;(4):64-68

Clinical case of severe steroid-dependent ulcerative colitis with complications of immunosuppressive therapy and basic treatment inefficacy is described. This clinical case demonstrates the possibility of achieving clinical remission in patients with ulcerative colitis with a complex medical history.

Keywords:

vedolizumab

entivio

ulcerative colitis

treatment

Authors:

Tarasova L.V.

Surgut State University;
I.N. Ulyanov Chuvash State University;
Surgut District Clinical Hospital

SPIN RSCI: 4125-7935
Scopus AuthorID: 35777248600
ORCID: 0000-0003-1496-0689

Busalaeva E.I.

Institute for Advanced Medical Studies;
I.N. Ulyanov Chuvash State University

Tsyganova Yu.V.

I.N. Ulyanov Chuvash State University

Zhudtlina N.V.

Surgut District Clinical Hospital

Matysyakevich I.D.

Surgut District Clinical Hospital

Received:

11.06.2020

Accepted:

24.06.2020

List of references:

Feagan BG, Bhayat F, Khalid M, Blake A, Travis SPL. Respiratory Tract Infections in Patients with Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. Journal of Crohn’s and Colitis. 2018;12(8):905-919. https://doi.org/10.1093/ecco-jcc/jjy047
Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839-851. https://doi.org/10.1136/gutjnl-2015-311079
Rosario M, Dirks NL, Milch C, Parikh A, Bargfrede M, Wyant T, Fedyk E, Fox I. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. Clinical Pharmacokinetics. 2017;56(11):1287-1301. https://doi.org/10.1007/s40262-017-0546-0
Ivashkin VT, Shelygin YuA, Khalif IL, Belousova EA, Shifrin OS Abdulganieva DI, Abdulkhakov RA, Alekseeva OP, Alekseenko SA, Achkasov SI, Baranovsky AYu, Bolikhov KV, Valujskikh EYu, Vardanyan AV, Veselov AV, Veselov VV, Golovenko AO, Golovenko OV, Grigoriev EG, Gubonina IV, Zhigalova TN, Kashnikov VN, Kizova EA, Knyazev OV, Kostenko NV, Kulyapin AV, Morozova NA, Muraviev AV, Nizov AA, Nikitina NV, Nikolaeva NN, Nikulina NV, Odintsova AKh, Osipenko MF, Pavlenko VV, Parfenov AI, Poluektova EA, Potapov AS, Rumyantsev VG, Svetlova IO, Sitkin SI, Timerbulatov VM, Tkachev AV, Tkachenko EI, Frolov SA, Khubezov DA, Chashkova EYu, Shapina MV, Shchukina OB, Yakovlev AA. Klinicheskie rekomendatsii Rossijskoj gastroenterologicheskoj assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostike i lecheniyu yazvennogo kolita. Koloproktologiya. 2017;1(59):6-30. (In Russ.)
Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn’s and Colitis. 2014;8:443-468. https://doi.org/10.1016/j.crohns.2013.12.013
Verstockt B, Ferrante M, Vermeire S, Van Assche G. New treatment options for inflammatory bowel diseases. Journal of Gastroenterogy. 2018;5:585-590. https://doi.org/10.1007/s00535-018-1449-z
Borisov SE, Lukina GV. Rekomendatsii po skriningu i monitoringu tuberkuleznoj infektsii u bol’nykh, poluchayushchikh genno-inzhenernye biologicheskie preparaty. Accessed April 20, 2020. (In Russ.) https://www.rheumatolog.ru
Stepashina TE, Tarasova LV, Busalaeva EI. The effectiveness of golimumab in severe ulcerative colitis with extraintestinal manifestations. Eksperimental’naya i klinicheskaya gastroenterologiya. 2015;12(124):116-119. (In Russ.)
Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Remikade. Registratsionnyj nomer П N012948/01. Accessed January 23, 2020. (In Russ.) https://grls.rosminzdrav.ru
Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Humira. Registratsionnyj nomer ЛС-002422-200814. Accessed January 23, 2020. (In Russ.) https://grls.rosminzdrav.ru
Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Entivio. RU №LP-003697. Accessed January 23, 2020. (In Russ.) https://grls.rosminzdrav.ru
Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Simponi. Registratsionnyj nomer LP-003825. Accessed January 23, 2020. (In Russ.) https://grls.rosminzdrav.ru
Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimization. Alimentary Pharmacology and Therapeutics. 2019; 49(4):408-418. https://doi.org/10.1111/apt.15113
Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, Smyth M. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. PLoS One. 2016;11(10): e0165435. https://doi.org/10.1371/journal.pone.0165435
Ng SC, Hilmi IN, Blake A, Bhayat F, Adsul S, Khan QR, Wu DC. Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflammatory Bowel Diseases. 2018;24(11):2431-2441. https://doi.org/10.1093/ibd/izy153
Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World Journal of Gastroenterology. 2018;24(23):2457-2467. https://doi.org/10.3748/wjg.v24.i23.2457
Loftus EV Jr, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, Danese S, D’Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M.Jr. Long-term efficacy of vedolizumab for ulcerative colitis. Journal of Crohn’s and Colitis. 2017;11(4):400-411. https://doi.org/10.1093/ecco-jcc/jjw177
Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936. https://doi.org/10.1053/j.gastro.2008.01.012

Close metadata